Synonym
Domperidone; Motilium; Domperidona; KW 5338; KW5338; KW-5338; NSC 299589; NSC299589; NSC-299589; R33812; R-33812; R 33812
IUPAC/Chemical Name
5-chloro-1-(1-(3-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)propyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one
InChi Key
FGXWKSZFVQUSTL-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H24ClN5O2/c23-15-6-7-20-18(14-15)25-22(30)28(20)16-8-12-26(13-9-16)10-3-11-27-19-5-2-1-4-17(19)24-21(27)29/h1-2,4-7,14,16H,3,8-13H2,(H,24,29)(H,25,30)
SMILES Code
O=C1NC2=CC(Cl)=CC=C2N1C3CCN(CCCN4C5=CC=CC=C5NC4=O)CC3
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
Domperidone (R33812) is an orally active and selective dopamine-2 receptor antagonist.
In vitro activity:
This study found that domperidone, a dopamine D2 receptor antagonist, significantly enhanced the replication of an OAd in human tumour cells, including human pancreatic tumour cells, by two-fivefold, resulting in improvement of OAd-mediated tumour cell killing activities. The E1A mRNA levels were significantly increased in domperidone-pre-treated cells following OAd infection, which contributed to the promotion of OAd replication.
Reference: J Gen Virol. 2022 Jun;103(6). https://pubmed.ncbi.nlm.nih.gov/35731650/
In vivo activity:
This study provides preliminary results on the ability of domperidone to improve SC and reduce anti-L. infantum antibody titers, globulins, gamma globulins and CRP in dogs with leishmaniosis and CKD.
Reference: Parasit Vectors. 2021 Oct 10;14(1):525. https://pubmed.ncbi.nlm.nih.gov/34629081/
|
Solvent |
mg/mL |
mM |
| Solubility |
| DMF |
10.0 |
0.23 |
| DMSO |
36.0 |
84.52 |
| DMSO:PBS (pH 7.2) (1:1) |
0.5 |
1.17 |
| Ethanol |
1.0 |
2.35 |
| Water |
0.7 |
1.57 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
425.91
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
1. Nishimae F, Sakurai F, Ono R, Onishi R, Takayama K, Mizuguchi H. A dopamine antagonist, domperidone enhances the replication of an oncolytic adenovirus in human tumour cells. J Gen Virol. 2022 Jun;103(6). doi: 10.1099/jgv.0.001752. PMID: 35731650.
2. Youssef AS, Parkman HP, Nagar S. Domperidone interacts with pioglitazone but not with ondansetron via common CYP metabolism in vitro. Xenobiotica. 2014 Sep;44(9):792-803. doi: 10.3109/00498254.2014.899406. Epub 2014 Mar 18. PMID: 24641107.
3. Cavalera MA, Gernone F, Uva A, D'Ippolito P, Roura X, Paltrinieri S, Zatelli A. Effect of domperidone (leisguard®) on antibody titers, inflammatory markers and creatinine in dogs with leishmaniosis and chronic kidney disease. Parasit Vectors. 2021 Oct 10;14(1):525. doi: 10.1186/s13071-021-05030-8. PMID: 34629081; PMCID: PMC8504065.
4. Bhat SK, Ganesh CB. Domperidone treatment attenuates stress-induced suppression of reproduction in viviparous mosquitofish Gambusia affinis. J Fish Biol. 2020 Jan;96(1):37-48. doi: 10.1111/jfb.14183. Epub 2019 Nov 19. PMID: 31648360.
In vitro protocol:
1. Nishimae F, Sakurai F, Ono R, Onishi R, Takayama K, Mizuguchi H. A dopamine antagonist, domperidone enhances the replication of an oncolytic adenovirus in human tumour cells. J Gen Virol. 2022 Jun;103(6). doi: 10.1099/jgv.0.001752. PMID: 35731650.
2. Youssef AS, Parkman HP, Nagar S. Domperidone interacts with pioglitazone but not with ondansetron via common CYP metabolism in vitro. Xenobiotica. 2014 Sep;44(9):792-803. doi: 10.3109/00498254.2014.899406. Epub 2014 Mar 18. PMID: 24641107.
In vivo protocol:
1. Cavalera MA, Gernone F, Uva A, D'Ippolito P, Roura X, Paltrinieri S, Zatelli A. Effect of domperidone (leisguard®) on antibody titers, inflammatory markers and creatinine in dogs with leishmaniosis and chronic kidney disease. Parasit Vectors. 2021 Oct 10;14(1):525. doi: 10.1186/s13071-021-05030-8. PMID: 34629081; PMCID: PMC8504065.
2. Bhat SK, Ganesh CB. Domperidone treatment attenuates stress-induced suppression of reproduction in viviparous mosquitofish Gambusia affinis. J Fish Biol. 2020 Jan;96(1):37-48. doi: 10.1111/jfb.14183. Epub 2019 Nov 19. PMID: 31648360.
1: Buffery PJ, Strother RM. Domperidone safety: a mini-review of the science of QT prolongation and clinical implications of recent global regulatory recommendations. N Z Med J. 2015 Jun 12;128(1416):66-74. Review. PubMed PMID: 26117678.
2: Marzi M, Weitz D, Avila A, Molina G, Caraballo L, Piskulic L. [Cardiac adverse effects of domperidone in adult patients: a systematic review]. Rev Med Chil. 2015 Jan;143(1):14-21. doi: 10.4067/S0034-98872015000100002. Review. Spanish. PubMed PMID: 25860264.
3: Makari J, Cameron K, Battistella M. Domperidone-associated sudden cardiac death in the general population and implications for use in patients undergoing hemodialysis: a literature review. Can J Hosp Pharm. 2014 Nov;67(6):441-6. Review. PubMed PMID: 25548402; PubMed Central PMCID: PMC4275141.
4: Phan H, DeReese A, Day AJ, Carvalho M. The dual role of domperidone in gastroparesis and lactation. Int J Pharm Compd. 2014 May-Jun;18(3):203-7. Review. PubMed PMID: 25306766.
5: Doggrell SA, Hancox JC. Cardiac safety concerns for domperidone, an antiemetic and prokinetic, and galactogogue medicine. Expert Opin Drug Saf. 2014 Jan;13(1):131-8. doi: 10.1517/14740338.2014.851193. Epub 2013 Oct 23. Review. PubMed PMID: 24147629.
6: Hondeghem LM. Domperidone: limited benefits with significant risk for sudden cardiac death. J Cardiovasc Pharmacol. 2013 Mar;61(3):218-25. doi: 10.1097/FJC.0b013e31827afd0d. Review. PubMed PMID: 23188128.
7: van Roeden SE, Belle-van Meerkerk G, van Tuyl SA, van de Ree MA, Muller AF. [Domperidone and the risk of sudden cardiac death]. Ned Tijdschr Geneeskd. 2013;157(45):A6770. Review. Dutch. PubMed PMID: 24191928.
8: Scott B. Question 2. How effective is domperidone at reducing symptoms of gastro-oesophageal reflux in infants? Arch Dis Child. 2012 Aug;97(8):752-5. doi: 10.1136/archdischild-2012-302183. Review. PubMed PMID: 22859430.
9: Rossi M, Giorgi G. Domperidone and long QT syndrome. Curr Drug Saf. 2010 Jul 2;5(3):257-62. Review. PubMed PMID: 20394569.
10: Sugumar A, Singh A, Pasricha PJ. A systematic review of the efficacy of domperidone for the treatment of diabetic gastroparesis. Clin Gastroenterol Hepatol. 2008 Jul;6(7):726-33. doi: 10.1016/j.cgh.2008.02.065. Epub 2008 Jun 4. Review. PubMed PMID: 18524689.
11: Reddymasu SC, Soykan I, McCallum RW. Domperidone: review of pharmacology and clinical applications in gastroenterology. Am J Gastroenterol. 2007 Sep;102(9):2036-45. Epub 2007 May 3. Review. PubMed PMID: 17488253.
12: Ahmad N, Keith-Ferris J, Gooden E, Abell T. Making a case for domperidone in the treatment of gastrointestinal motility disorders. Curr Opin Pharmacol. 2006 Dec;6(6):571-6. Epub 2006 Sep 25. Review. PubMed PMID: 16997628.
13: Pritchard DS, Baber N, Stephenson T. Should domperidone be used for the treatment of gastro-oesophageal reflux in children? Systematic review of randomized controlled trials in children aged 1 month to 11 years old. Br J Clin Pharmacol. 2005 Jun;59(6):725-9. Review. PubMed PMID: 15948939; PubMed Central PMCID: PMC1884866.
14: Henderson A. Domperidone. Discovering new choices for lactating mothers. AWHONN Lifelines. 2003 Feb-Mar;7(1):54-60. Review. PubMed PMID: 12674062.
15: Prakash A, Wagstaff AJ. Domperidone. A review of its use in diabetic gastropathy. Drugs. 1998 Sep;56(3):429-45. Review. PubMed PMID: 9777316.
16: Zapata P, Iturriaga R, Larraín C. Domperidone as a tool to assess the role of dopamine within carotid body chemoreception. Adv Exp Med Biol. 1996;410:291-7. Review. PubMed PMID: 9030314.
17: Brown CK, Khanderia U. Use of metoclopramide, domperidone, and cisapride in the management of diabetic gastroparesis. Clin Pharm. 1990 May;9(5):357-65. Review. PubMed PMID: 2190745.
18: Cherian S, Sachdev HP, Puri RK. Domperidone. Indian Pediatr. 1989 Sep;26(9):932-5. Review. PubMed PMID: 2699318.
19: Champion MC. Domperidone. Gen Pharmacol. 1988;19(4):499-505. Review. PubMed PMID: 3044918.
20: Champion MC, Hartnett M, Yen M. Domperidone, a new dopamine antagonist. CMAJ. 1986 Sep 1;135(5):457-61. Review. PubMed PMID: 3527396; PubMed Central PMCID: PMC1491526.
